With President-elect Trump returning to the White House and Republicans controlling Congress, significant changes to the Medicaid expansion are expected. This data note provides key facts on the Medicaid expansion, highlighting the financial and coverage impacts of any changes across states that voted for President-elect Trump and those that voted for Vice President Harris.
Lines at the desk, phones ringing off the hook and a stack of insurance questions waiting to be resolved — this is the daily reality for many patient access teams. Today’s patients find these “front door” bottlenecks in healthcare particularly frustrating, especially since they can envision how much smoother the process could be with the…
On the campaign trail, Donald Trump tried mightily to reassure abortion rights supporters, vowing he would not sign into law a nationwide abortion ban even if Congress sent him one. But once he returns to the White House in January, Trump can make abortions difficult — or illegal —across the United States without Congress taking…
Ryan Wettstein Nauman was inconsolable one evening last December. After being put down for bed, the 3-year-old from Peoria, Illinois, just kept crying and crying and crying, and nothing would calm her down. Her mother, Maggi Wettstein, remembered fearing it could be a yeast or urinary tract infection, something they had been dealing with during…
Leaders from three health systems — Providence, OSF HealthCare and UMass Memorial Health — detailed how their organizations are maximizing hybrid and home-based care models during a recent panel. The post How 3 Health Systems Are Scaling Hybrid & Home-Based Models appeared first on MedCity News.
Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy. The post Weight Loss With Amgen Drug in…
This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.
In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the company recently received through the Sprint for Women’s Health program. The post MedCity FemFwd: How Celmatix is Using ARPA-H’s Sprint for Women’s Health Funding appeared first on MedCity News.
The Health Resources and Services Administration is making a $52 million investment in 54 health centers to support the health needs of those leaving incarceration. The post HRSA Commits $52M to Health Centers Supporting People Leaving Incarceration appeared first on MedCity News.
Joining Matthew Holt (@boltyboy) on #THCBGang on Tuesday November 26 at 1PM PT 4PM ET are THCB regular writer and ponderer of odd juxtapositions Kim Bellard (@kimbbellard); medical historian Mike Magee (@drmikemagee); and a new guest from Marsh McLennan, Employee Benefits Consultant Ryan Koo (@RyanKoo). You can see the video below & if you’d rather listen…